Synapse - Works

Results (115372)

Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

Meeting Abstract

Chan, J.; Geyer, S.; Ou, F. S.; Knopp, M.; Behr, S.; Zemla, T.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)

Meeting Abstract

Spicer, J. D.; Gao, S.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; Chen, K. N.; Dooms, C.; Majem, M.; Eigendorff, E.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)

Meeting Abstract

Ho, A. L.; Adkins, D. R.; Hanna, G. J.; Bruce, J.; Ahn, M. J.; Iglesias Docampo, L.; Kang, H.; Wong, D. J.; Psyrri, A.; Gillison, M.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial

Meeting Abstract

Eskander, R. N.; Sill, M.; Miller, A.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M. S.; Canturia, G.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)

Meeting Abstract

Liu, J. F.; Brady, M.; Matulonis, U. A.; Miller, A.; Kohn, E. C.; Swisher, E.; Tew, W.; Cloven, N.; Muller, C.; Bender, D.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study

Meeting Abstract

Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Oh, D. Y.; Banerjee, S.; Gonzalez Martin, A.; Jung, K. H.; Lugowska, I.; Manso, L. M.; Manzano, A.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study

Meeting Abstract

Shiu, K. K.; André, T.; Kim, T. W.; Vittrup Jensen, B.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; Alcaide-Garcia, J.; Gibbs, P.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

Meeting Abstract

Sridhar, S.; O'Donnell, P. H.; Flaig, T. W.; Rosenberg, J. E.; Hoimes, C. J.; Milowsky, M. I.; Srinivas, S.; George, S.; McKay, R. R.; Petrylak, D. P.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Consensus views on research priorities for cancer survivorship in older adulthood: A Delphi study

Meeting Abstract

Drury, A.; O'Brien, A.; O'Connell, L.; Cosgrave, S.; Hannan, M.; Smyth, C.; Fessele, K.; Sheehan, S.; Harkin, M.; Rogers, L.
Annals of Oncology (2023)

Fulltext@MSK | Save

Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial

Meeting Abstract

Bardia, A.; Jhaveri, K.; Im, S. A.; Pernas Simon, S.; De Laurentiis, M.; Wang, S.; Martinez, N.; Santos Borges, G.; Cescon, D. W.; Hattori, M.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save